Halozyme Therapeutics (HALO) said Monday that Johnson & Johnson's (JNJ) Janssen-Cilag International has received a positive opinion in Europe recommending an extension of marketing authorization for a subcutaneous formulation of Rybrevant in treating non-small cell lung cancer.

The positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use is for Rybrevant in combination with Lazcluze and as a monotherapy, Halozyme said.

The company said subcutaneous Rybrevant is co-formulated with its Enhanze drug delivery technology.